Although IL-1 may serve as a pharmacological inflammatory target for ALS, this study had some limitations such as a small number of patients, not measuring the inflammatory parameters in CSF, and lacking a double-blinded placebo control group. The gene discussed is IL1B; the disease is amyotrophic lateral sclerosis.